AstraZeneca Q2 Results and Elecoglipron Phase 3 Launch; TGA GLP-1 NAION Warning
AstraZeneca Q2 Results and Elecoglipron Phase 3 Launch, TGA GLP-1 NAION Warning, AIDS 2026 Main Opens
AstraZeneca Q2 beats + Semaglutide Phase 3 kickoff. AIDS 2026 opens. Australia TGA GLP-1 NAION warning. Hims $440M peptide analyst perspective.
4 stories · Covering clinical trials, regulatory affairs, and the industry
Editor's Note
Monday's peptide news centers on AstraZeneca's Q2 2026 earnings report released before market open, which delivered a top-line and bottom-line consensus beat (core EPS $2.63 +18% constant currency, revenue $15.38 billion +5%) alongside a significant pipeline milestone: elecoglipron, the oral small-molecule GLP-1 receptor agonist that AstraZeneca in-licensed and advanced through Phase 2 VISTA and SOLSTICE with ADA 2026 data, has now entered a full Phase 3 program in Q2 across the EMBOLD obesity trials, the ELUMINATE type 2 diabetes trials (including combinations with dapagliflozin), and cardiovascular and kidney outcome studies. AstraZeneca is now the third major competitor to Novo Nordisk and Eli Lilly in the oral GLP-1 market. Separately from earnings, the 26th International AIDS Conference (AIDS 2026) main session opens Monday, July 27, at Riocentro in Rio de Janeiro, featuring the UNAIDS 'United to End AIDS' 2025 data report release, which documents the severity of 2025 HIV funding cuts and presents the WHO's first global mid-term assessment of progress under the Global Health Sector Strategies (the halfway point toward the 2030 targets). Australia's Therapeutics Goods Administration (TGA) issued a class-wide update warning about the risk of non-arteritic anterior ischemic optic neuropathy (NAION) for GLP-1 receptor agonists; the Advisory Committee on Medicines concluded that evidence supports this signal for semaglutide (23 cases) but not for dulaglutide or tirzepatide (10 cases). Following PCAC, analyst coverage of Hims & Hers Health (NYSE: HIMS) diverged, with BofA setting a price target of $36 and Canaccord at $40 regarding the peptide opportunity, while the 6-18-month FDA rulemaking timeline tempers near-term catalyst expectations.
1
AstraZeneca (NYSE: AZN) reports Q2 2026 earnings before market open Monday, July 27, 2026. Core EPS of $2.63 (+18% constant currency), beating consensus of $2.48. Revenue reached $15.38 billion (+5%), in line with consensus of $15.39 billion. The company advanced Elecoglipron, an oral small-molecule GLP-1 receptor agonist, into the full Phase 3 program across EMBOLD obesity trials, ELUMINATE Type 2 diabetes trials (including monotherapy and combination with dapagliflozin), and cardiovascular and kidney outcome trials. This positions AstraZeneca to challenge Novo Nordisk and Eli Lilly in the oral GLP-1 market. Additionally, a positive Q2 update on Tozorakimab raised peak sales projections above $5 billion from $3 billion.
AstraZeneca (NYSE: AZN) reported Q2 2026 earnings before the market opened on Monday, July 27, 2026, with core earnings per share of $2.63 for the three months ended June 30 (+18% in constant currency), beating consensus estimates of $2.48. Revenue of $15.38 billion matched consensus expectations of $15.39 billion (+5%). Analysts focused on the earnings call update regarding the pipeline: elecoglipron, an oral small-molecule GLP-1 receptor agonist that AstraZeneca in-licensed and advanced through Phase 2 trials VISTA and SOLSTICE (which reported positive data at the ADA 2026 Scientific Sessions in June), has now entered a full Phase 3 program in Q2 2026. The Phase 3 program includes the EMBOLD trials in adults with obesity or overweight (with and without type 2 diabetes), the ELUMINATE trials in adults with type 2 diabetes (as monotherapy and in combination with dapagliflozin), and long-term cardiovascular and kidney outcome trials. AstraZeneca is now the third major player competing with Novo Nordisk and Eli Lilly in the oral GLP-1 market, alongside oral semaglutide/Ozempic and orforglipron (Foundayo, FDA-approved in April 2026). Separately, AstraZeneca revised its peak sales forecast for tozorakimab (an experimental respiratory treatment) upward to above $5 billion from the previous estimate of $3 billion. AZN shares rose approximately 1.7% during London trading on Monday morning.
2
26th International AIDS Conference (AIDS 2026) Main Conference Opens Monday, July 27, 2026 at Riocentro in Rio de Janeiro, Brazil (Opening Ceremony 15:00-16:30 Local Time in the Global Village) With Release of the UNAIDS "United to End AIDS" 2025 Data Report Documenting the Severity of 2025 HIV Funding Cuts and the WHO's First Global Mid-Term Assessment of Progress Under the Global Health Sector Strategies on HIV, Viral Hepatitis, and Sexually Transmitted Infections Marking the Halfway Point to the 2030 Targets — Peptide-Adjacent HIV Modality Content This Week Includes Gilead Sciences Lenacapavir PURPOSE 1 and PURPOSE 2 Long-Term Extension Data and Gilead-Merck Islatravir/Lenacapavir Phase 3 ISLEND-1 and ISLEND-2 Late-Breaker Wednesday, July 29
The 26th International AIDS Conference (AIDS 2026) main conference opened Monday, July 27, 2026, at Riocentro in Rio de Janeiro, Brazil. The opening ceremony ran from 15:00 to 16:30 local time in the Global Village. UNAIDS released its 'United to End AIDS' 2025 data report on the opening day, documenting the severity of 2025 HIV funding cuts and their impact on HIV prevention, community services, key populations, and the sustainability of the global AIDS response. The WHO launched its first global mid-term assessment of progress under the Global Health Sector Strategies on HIV, viral hepatitis, and sexually transmitted infections, marking the halfway point to the 2030 targets and providing a comprehensive overview of where the world stands on the SDG 3.3 targets. Peptide-adjacent HIV modality content this week includes Gilead Sciences's twice-yearly lenacapavir (first-in-class HIV capsid inhibitor) PURPOSE 1 and PURPOSE 2 long-term extension data, as well as detailed late-breaker data from the Gilead-Merck once-weekly oral islatravir/lenacapavir Phase 3 ISLEND-1 and ISLEND-2 studies scheduled for Wednesday, July 29. Merck plans separate presentations across daily, weekly, and monthly HIV treatment and prevention pipeline assets, including alimatravir (MK-8527), the investigational once-monthly oral HIV prevention pill licensed on July 24 to Aspen Pharmacare and six other generic manufacturers for 129 low- and middle-income countries.
3
Australia's Therapeutics Goods Administration (TGA) Issues Class-Wide GLP-1 Receptor Agonist Product Warning Update on July 25, 2026 Regarding Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION), Adding Label Language to Trulicity (Dulaglutide), Ozempic (Semaglutide), Wegovy (Semaglutide), Mounjaro (Tirzepatide), and Saxenda (Liraglutide). The Advisory Committee on Medicines concluded that current evidence supports the signal for Semaglutide but not for Dulaglutide or Tirzepatide. 36 Total Cases of Optic Ischaemic Neuropathy Reported to the Australian Database of Adverse Event Notifications (DAEN): 23 for Semaglutide, 10 for Tirzepatide, and 3 for Liraglutide. Patients are advised to seek urgent medical attention for sudden vision loss.
Australia's Therapeutics Goods Administration (TGA) issued a class-wide product warning update on Saturday, July 25, 2026, regarding GLP-1 receptor agonists and non-arteritic anterior ischaemic optic neuropathy (NAION). NAION is a rare but severe eye disorder that can lead to permanent vision impairment, including blindness. No treatment has been shown to improve visual acuity outcomes after NAION onset. This label update applies to all five GLP-1 RA products currently marketed in Australia: Trulicity (dulaglutide, Eli Lilly), Ozempic (semaglutide, Novo Nordisk), Wegovy (semaglutide, Novo Nordisk), Mounjaro (tirzepatide, Eli Lilly), and Saxenda (liraglutide, Novo Nordisk). The Advisory Committee on Medicines concluded that current evidence supports the signal for semaglutide but not for dulaglutide or tirzepatide. A review of the Australian Database of Adverse Event Notifications (DAEN) identified 36 cases of optic ischaemic neuropathy associated with GLP-1 RAs, including 23 for semaglutide, 10 for tirzepatide, and 3 for liraglutide. Patients are advised to seek urgent medical attention for any sudden vision loss, including partial vision loss. This action by Australia follows the UK MHRA Drug Safety Update on semaglutide and NAION issued on February 5, 2026.
Post-PCAC Analyst View on Hims & Hers Health (NYSE: HIMS): BofA Securities raised its price target to $36, and Canaccord Genuity lifted theirs to $40, citing a peptide-compounding opportunity estimated at approximately $440 million in 2027 sales from the four recommended compounding peptides. Truist maintained its rating at $23, noting the 6-18-month FDA rulemaking timeline and concerns over uninsured patients. The peptide catalyst remains tempered by the advisory nature of the July 23-24 PCAC vote, which passed 6-of-7. Compounding pharmacies still cannot legally prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon under Section 503A today.
Post-PCAC analyst coverage of Hims & Hers Health (NYSE: HIMS) following the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 vote. BofA Securities raised its price target to $36 on the peptide-compounding opportunity, and Canaccord Genuity increased its target to $40, both citing the July 23-24 PCAC vote and Hims & Hers' acquired California peptide manufacturing facility. Analysts estimate that the four Day-1 recommended peptides (BPC-157, KPV, TB-500, MOTS-c) could generate approximately $440 million in Hims & Hers sales by 2027 if the FDA proceeds with Section 3A rulemaking. Truist Securities maintained its rating at $23, citing the 6-18-month FDA rulemaking timeline and continued demand from uninsured patients. Barclays stands at $39 (based on the Novo Nordisk partnership thesis). The upside from the peptide catalyst is tempered by the advisory nature of the PCAC outcome: compounding pharmacies still cannot legally prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon under Section 503A today because none of the six substances are on the Section 3A Bulks List. Adding each substance via FDA rulemaking will take 6-18 months from the date the agency decides to act. Hims shares closed near $28.50 last week after briefly rallying above $35 on the initial vote results.